LiberoThera is a drug discovery company targeting membrane proteins including GPCRs. Founded on the revolutionary research by Prof. Shigeyuki Yokoyama, Emeritus Professor at The University of Tokyo and Distinguished Senior Scientist at RIKEN, LiberoThera utilizes its cutting-edge cell-free protein expression system and non-natural amino acid technology which enable complexed membrane proteins to be prepared in natural forms with structural and functional integrity. LiberoThera is developing novel therapeutic candidates targeting physiologically important membrane proteins, such as GPCRs, in collaboration with multiple partners.
LiberoThera was founded in 2018 on the revolutionary research by Prof. Shigeyuki Yokoyama, Distinguished Senior Scientist at RIKEN. Under the support of NEDO-STS program, LiberoThera has established novel drug discovery platform utilizes its cutting-edge membrane protein synthesis and non-natural amino acid technology. LiberoThera is developing novel therapeutic candidates targeting physiologically important membrane proteins, such as GPCRs.
Many GPCRs are important drug targets for a variety of indications. However, due to the special structure of such targets, the development of antibody drugs against them has always been challenging. The structural membrane proteins prepared with LiberoThera’s propriate cell-free membrane synthesis technologies can provide a solution for drug discoveries targeting the complexed membrane proteins such as GPCRs.
- 1-9-10 Nihonbashi-Horidomecho Chuo-ku, Tokyo 103-0012 Nihonbashi Life Science Bldg. 7, 8F